Raltegravir News
Raltegravir currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Raltegravir with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection.
- Evidence level: L5
- Predicted indications (20):
- HIV infectious disease (99.9%)
- simian immunodeficiency virus infection (99.8%)
- feline acquired immunodeficiency syndrome (99.8%)
- neurodevelopmental disorder with ataxic gait, absent speech, and decreased cortical white matter (99.8%)
- AIDS (98.4%)
- AIDS related complex (96.5%)
- congenital human immunodeficiency virus (96.5%)
- obsolete familial combined hyperlipidemia (96.0%)
- fibroma of prostate (94.4%)
- breast fibrocystic disease (93.9%)
- benign reproductive system neoplasm (93.7%)
- Brenner tumor (93.6%)
- benign prostate phyllodes tumor (93.4%)
- blunt duct adenosis of breast (92.3%)
- apocrine adenosis of breast (92.3%)
- male reproductive organ cancer (92.1%)
- prostate cancer/brain cancer susceptibility (92.0%)
- benign mammary dysplasia (91.8%)
- prostate leiomyoma (91.1%)
- breast abscess (82.8%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.